September 2017

Edinburgh Molecular Imaging Commences Phase II European Cancer Trial

Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK, September 20, 2017 – Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase IIb clinical trial…